SCHEMBL20719141

SCHEMBL20719141

CCOC(=O)COc1c(F)cc(Br)cc1[N+](=O)[O-]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.46
CYP1A2 P05177 3/20 0.46
CYP2C19 P33261 3/20 0.46
SRD5A2 P31213 2/20 0.44
MAPT P10636 10/20 0.40
LMNA P02545 4/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
HPGD P15428 3/20 0.40
POLB P06746 2/20 0.40
KDM4E B2RXH2 2/20 0.40
HTT P42858 1/20 0.40
CASP6 P55212 1/20 0.40
ATM Q13315 1/20 0.40
CYP2C9 P11712 2/20 0.40
NPSR1 Q6W5P4 3/20 0.39
CYP3A4 P08684 1/20 0.39
NTSR1 P30989 1/20 0.39
MAPK1 P28482 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4288076 0.87 SRD5A2 (0.43) ALDH1A1CYP1A2CYP2C19SRD5A2MAPT
SCHEMBL16792433 0.87 SRD5A2 (0.46) ALDH1A1CYP1A2CYP2C19SRD5A2MAPT
SCHEMBL5335121 0.84 SRD5A2 (0.43) ALDH1A1CYP1A2CYP2C19SRD5A2MAPT
SCHEMBL30673301 0.84 GRIN2D (0.46) ALDH1A1CYP1A2SRD5A2MAPTLMNA
SCHEMBL26928539 0.84 GRIN2D (0.46) ALDH1A1CYP1A2SRD5A2MAPTLMNA
SCHEMBL16792371 0.80 NLRP3 (0.48) ALDH1A1CYP1A2CYP2C19SRD5A2MAPT
SCHEMBL29136555 0.78 MAPT (0.44) ALDH1A1CYP1A2CYP2C19MAPTLMNA
SCHEMBL29991195 0.78 MEN1 (0.38) ALDH1A1SRD5A2MAPTLMNAMEN1
SCHEMBL6960 0.77 ALDH1A1 (0.56) ALDH1A1CYP1A2CYP2C19MAPTLMNA
SCHEMBL9863069 0.76 MAPT (0.50) ALDH1A1CYP1A2CYP2C19MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250177408-A1 INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF Etern Therapeutics Hongkong Limited (CN) 2025-06-05 US disclosed
EP-4484420-A1 INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF Etern Biopharma (Shanghai) Co., Ltd. (CN) 2025-01-01 EP disclosed
WO-2023155927-A1 INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 上海奕拓医药科技有限责任公司 2023-08-24 WO disclosed
US-10590083-B2 Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2020-03-17 US disclosed
US-10399944-B2 Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2019-09-03 US disclosed
US-10336701-B2 Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2019-07-02 US disclosed
US-20190047961-A1 PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2019-02-14 US disclosed
US-20190047959-A1 PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2019-02-14 US disclosed
US-20190047960-A1 PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2019-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10336701-B2 Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists PTGER3, PTGER1, PTGER2 ALDH1A1 2314/4885CYP1A2 281/4885CYP2C19 246/4885
US-10590083-B2 Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists PTGER3, PTGER1, PTGER2 ALDH1A1 1953/4885CYP1A2 302/4885CYP2C19 249/4885
US-20190047960-A1 PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS PTGER3, PTGER1, PTGER2 ALDH1A1 2314/4885CYP1A2 281/4885CYP2C19 246/4885
US-20190047959-A1 PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS PTGER3, PTGER1, PTGER2 ALDH1A1 1953/4885CYP1A2 302/4885CYP2C19 249/4885
US-10399944-B2 Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists PTGER3, PTGER1, PTGER2 ALDH1A1 2320/4885CYP1A2 321/4885CYP2C19 240/4885
US-20250177408-A1 INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF YAP1, YES1, TEAD2 ALDH1A1 3327/4885CYP1A2 2867/4885CYP2C19 3022/4885
US-20190047961-A1 PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS PTGER3, PTGER1, PTGER2 ALDH1A1 2320/4885CYP1A2 321/4885CYP2C19 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.